[Hepatocardiac disorders : Interactions between two organ systems].
暂无分享,去创建一个
S. Kluge | T. Horvatits | A. Drolz | K. Roedl | V. Fuhrmann | K. Rutter
[1] A. Shujaat,et al. Effect of PAH Specific Therapy on Pulmonary Hemodynamics and Six-Minute Walk Distance in Portopulmonary Hypertension: A Systematic Review and Meta-Analysis , 2014, Pulmonary medicine.
[2] M. Fallon,et al. MELD Exceptions for Portopulmonary Hypertension: Current Policy and Future Implementation , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] Simona Bota,et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. , 2014, Gastroenterology.
[4] C. Zauner,et al. Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. , 2014, Journal of hepatology.
[5] F. Bendtsen,et al. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance , 2014, Nature Reviews Gastroenterology &Hepatology.
[6] T. Horvatits,et al. Therapeutic options in pulmonary hepatic vascular diseases , 2014, Expert review of clinical pharmacology.
[7] P. Schulze,et al. Recent Advances in the Diagnosis and Management of Cirrhosis-Associated Cardiomyopathy in Liver Transplant Candidates: Advanced Echo Imaging, Cardiac Biomarkers, and Advanced Heart Failure Therapies , 2014, Clinical Medicine Insights. Cardiology.
[8] R. Kumar,et al. Correction: Updated clinical classification of pulmonary hypertension (Journal of the American College of Cardiology (2013) 62, (D34-D41)) , 2014 .
[9] V. Fuhrmann,et al. Schockleber und Cholestase beim kritisch Kranken , 2014, Medizinische Klinik - Intensivmedizin und Notfallmedizin.
[10] S. Kluge,et al. Pulmonale Komplikationen bei Lebererkrankungen , 2014, Medizinische Klinik - Intensivmedizin und Notfallmedizin.
[11] Toru Satoh,et al. Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.
[12] M. Rodríguez-Gandía,et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine , 2013, Hepatology.
[13] C. Zauner,et al. Clinical impact of arterial ammonia levels in ICU patients with different liver diseases , 2013, Intensive Care Medicine.
[14] C. Datz,et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) , 2013, Wiener klinische Wochenschrift.
[15] M. Trauner,et al. Hypoxic liver injury and cholestasis in critically ill patients , 2013, Current opinion in critical care.
[16] M. Fallon,et al. Pulmonary vascular complications of liver disease. , 2013, American journal of respiratory and critical care medicine.
[17] P. Angeli,et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms , 2013, Hepatology.
[18] Horst Olschewski,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[19] M. Sitges,et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. , 2013, Journal of hepatology.
[20] C. Zauner,et al. Jaundice increases the rate of complications and one‐year mortality in patients with hypoxic hepatitis , 2012, Hepatology.
[21] N. Ortiz-Olvera,et al. Anatomical cardiac alterations in liver cirrhosis: an autopsy study. , 2011, Annals of hepatology.
[22] C. Madl,et al. Impact of hypoxic hepatitis on mortality in the intensive care unit , 2011, Intensive Care Medicine.
[23] Christian Melot,et al. Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites , 2010, Hepatology.
[24] C. Madl,et al. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients , 2009, Intensive Care Medicine.
[25] R. Wiesner,et al. Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] M. Humbert,et al. Portopulmonary hypertension: survival and prognostic factors. , 2008, American journal of respiratory and critical care medicine.
[27] J. Henriksen,et al. Cardiovascular complications of cirrhosis , 2008, Postgraduate Medical Journal.
[28] C. Madl,et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. , 2006, Gastroenterology.
[29] R. Rodríguez-Roisín,et al. Pulmonary–Hepatic vascular Disorders (PHD) , 2004, European Respiratory Journal.
[30] J. Henriksen,et al. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. , 2004, Journal of hepatology.
[31] J. Henriksen,et al. Ablation of haemodynamically unstable right ventricular outflow tract ventricular tachycardia guided by non-contact mapping , 2002, Heart.
[32] C. A. Ward,et al. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. , 2001, Gastroenterology.
[33] A. Delannoy,et al. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: A case‐controlled, hemodynamic study of 17 consecutive cases , 1999, Hepatology.